As the FTC continues to crack down on pharmaceutical manufacturers’ allegedly improper listing of patents in the FDA Orange Book, counsel for Teva and Amneal presented oral arguments in the Court of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback